ASXL1 and anemia: At the same time, patients with BPDCN often share features with patients with AML, including anemia, blasts in the bone marrow, and somatic point mutations in genes such as: TET2, ASXL1, IDH2, and NPM1. BPDCN can also progress to AML5, has been associated with co-existence of/or prior MDS/CMML in ~20% of patients in one major cohort27, and has been detected in a patient with Felty’s syndrome and myelodysplastic syndrome5,28.